Lupin has filed an ANDA for a generic version of Depomed’s Type 2 diabetes medication Glumetza. The company sent Depomed a Paragraph IV certification notice claiming four patents on the drug are invalid and will not be infringed by Lupin’s manufacturing and selling of Glumetza (metformin HCl), Depomed says in a statement last week.
Washington Drug Letter